nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

23.06.2018 | Original Article

Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients

verfasst von: Sreenivasulu Palugulla, Panneer Devaraju, Smita Kayal, Sunil K. Narayan, Jayanthi Mathaiyan

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Digestive tract cancer patients treated with oxaliplatin are often associated with the development of peripheral neuropathy. The aim of the present study is to identify the influence of single-nucleotide polymorphisms (SNPs) in genes involved in oxaliplatin metabolism, cell cycle control, detoxification or excretion pathways with the development of oxaliplatin-induced acute peripheral neuropathy (acute OXAIPN) and its severity among digestive tract cancer patients treated with oxaliplatin-based chemotherapy.

Patients and methods

A total of 228 digestive tract cancer patients undergoing with the oxaliplatin-based chemotherapy between November 2014 and December 2016 were included in the current study. Genomic DNA was extracted from peripheral blood by standard phenol–chloroform method. Genotyping of five SNPs in four genes [GSTP₁ (rs1965), ABCG2 (rs3114018), CCNH (rs2230641, rs3093816), AGXT (rs4426527)] was carried out by Real-Time TaqMan SNP genotyping assay.

Results

We found that the two genetic variants rs2230641 and rs3093816 in cyclin H (CCNH) gene were significantly associated with both the incidence and severity of acute OXAIPN. For CCNH-rs2230641 (AA vs AG+GG; dominant model) Incidence: OR 2.62, 95% CI 1.44–4.75, p = 0.001, severity; OR 4.64, 95% CI 1.58–13.62, p = 0.002. For CCNH-rs3093816 (AA vs AG+GG; dominant model); incidence: OR 3.43, 95% CI 1.57–7.50, p = 0.001; severity: OR 2.36, 95% CI 1.05–5.30, p = 0.033.

Conclusions

The results of the present study found significant association between CCNH polymorphisms and acute OXAIPN development. However, further studies are warranted from independent groups to validate our study results.

Nur mit Berechtigung zugänglich

Hill EJ, Nicolay NH, Middleton MR, Sharma RA (2012) Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research? Crit Rev Oncol Hematol 83:353–387CrossRefPubMed

Pilancı KN, Saglam S, Okyar A, Yucel S, Pala-Kara Z, Ordu C et al (2016) Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: a phase II Brunch regimen study. Cancer Chemother Pharmacol 78:143–150CrossRefPubMed

Chao Y, Hsieh J-S, Yeh H-T, Su Y-C, Wu C-C, Chen J-S et al (2014) A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemother Pharmacol 73:799–806CrossRefPubMedPubMedCentral

André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351CrossRefPubMed

Isayama H, Nakai Y, Yamamoto K, Sasaki T, Mizuno S, Yagioka H et al (2011) Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Oncology 80(1–2):97–101CrossRefPubMed

Wang Y, Zhuang R, Yu Y, Yu S, Hou J, Ji Y et al (2016) Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget 7:76298–76307PubMedPubMedCentral

Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E et al (2006) Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 94:481–485CrossRefPubMedPubMedCentral

Argyriou AA (2015) Updates on oxaliplatin-induced peripheral neurotoxicity (OXAIPN). Toxics 3:187–197CrossRefPubMedPubMedCentral

Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP (2014) Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 6:135–147CrossRefPubMedPubMedCentral

10.

Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15–49CrossRefPubMed

11.

Park SB, Goldstein D, Krishnan AV, Lin CS-Y, Friedlander ML, Cassidy J et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63:419–437CrossRefPubMed

12.

Beijers AJM, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22:1999–2007CrossRefPubMed

13.

Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387–392CrossRefPubMed

14.

Sereno M, Gutiérrez-Gutiérrez G, Gómez-Raposo C, López-Gómez M, Merino-Salvador M, Tébar FZ et al (2014) Oxaliplatin induced-neuropathy in digestive tumors. Crit Rev Oncol Hematol 89:166–178CrossRefPubMed

15.

Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A et al (2010) Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 48:729–734CrossRefPubMed

16.

Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T et al (2010) Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol 34:189–193CrossRefPubMed

17.

Custodio A, Moreno-Rubio J, Aparicio J, Gallego-Plazas J, Yaya R, Maurel J et al (2014) Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol 25:398–403CrossRefPubMed

18.

Won H-H, Lee J, Park JO, Park YS, Lim HY, Kang WK et al (2012) Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 118:2828–2836CrossRefPubMed

19.

Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J et al (2013) Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer 119:3570–3577CrossRefPubMed

20.

Kweekel DM, Antonini NF, Nortier JWR, Punt CJA, Gelderblom H, Guchelaar H-J (2009) Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. Br J Cancer 101:357–362CrossRefPubMedPubMedCentral

21.

Tamang R, Singh L, Thangaraj K (2012) Complex genetic origin of Indian populations and its implications. J Biosci 37:911–919CrossRefPubMed

22.

Velasco R, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P et al (2014) Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 85:392–398CrossRefPubMed

23.

Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M et al (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119:438–444CrossRefPubMed

24.

Blin N, Stafford DW (1976) A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 3:2303–2308CrossRefPubMedPubMedCentral

25.

Lewis CM (2002) Genetic association studies: design, analysis and interpretation. Br Bioinform 3(2):146–153CrossRef

26.

Robertson J, Barr R, Shulman LN, Forte GB, Magrini N (2016) Essential medicines for cancer: WHO recommendations and national priorities. Bull World Health Organ 94:735–742CrossRefPubMedPubMedCentral

27.

Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D et al (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25:1247–1254CrossRefPubMed

28.

Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot M-A (2006) Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12:3050–3056CrossRefPubMed

29.

Wu G, Cao J, Peng C, Yang H, Cui Z, Zhao J et al (2011) Temporal and spatial expression of cyclin H in rat spinal cord injury. Neuromol Med 13:187–196CrossRef

30.

Lolli G, Johnson LN (2005) CAK—cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle Georget Tex 4:572–577

31.

Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding—PubMed—NCBI [Internet]. [cited 2017 Aug 28]. https://www.ncbi.nlm.nih.gov/pubmed/16797073

32.

Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW (1994) Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 37:1380–1385CrossRefPubMed

33.

Murali A, Nalinakumari KR, Thomas S, Kannan S (2014) Association of single nucleotide polymorphisms in cell cycle regulatory genes with oral cancer susceptibility. Br J Oral Maxillofac Surg 52:652–658CrossRefPubMed

34.

Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D et al (2016) Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). Ann Oncol 27:1143–1148CrossRefPubMed

35.

Grothey A, McLeod HL, Green EM, Sargent DJ, Fuchs C, Ramanathan RK et al (2005) Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. J Clin Oncol 23:3509CrossRef

36.

Peng Z, Wang Q, Gao J, Ji Z, Yuan J, Tian Y et al (2013) Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemother Pharmacol 72:305–314CrossRefPubMed

37.

Cobos A, Sánchez P, Aguado J, Carrasco JL (2011) Methodological quality in pharmacogenetic studies with binary assessment of treatment response: a review. Pharmacogenet Genomics 21:243–250CrossRefPubMed

Titel: Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients
verfasst von: Sreenivasulu Palugulla
Panneer Devaraju
Smita Kayal
Sunil K. Narayan
Jayanthi Mathaiyan
Publikationsdatum: 23.06.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2018
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3629-1

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients

Abstract

Purpose

Patients and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Patients and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies

Natural low- and high-density lipoproteins as mighty bio-nanocarriers for anticancer drug delivery

Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil® or Caelyx® in advanced ovarian cancer

A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie